Genesis Therapeutics is using AI to optimize and accelerate drug discovery by exploring novel protein targets and untapped chemical space to identify new medicines for severe diseases. To do this, Genesis has built their advanced molecular AI platform (PotentialNet) that uses 3D spatial graph modeling, molecular simulations and a massively scalable molecular generation engine to generate novel drug candidates. PotentialNet intuits the 3D structural dynamics of protein-ligand dynamics, providing predictive accuracy for drug potency and selectivity for data-poor protein targets. Following hit identification, Genesis uses their GEMS platform to generate billions of virtual molecules optimizing for lead-likeness and easy synthesizability to explore further only the most promising candidates.